Is there any prognostically different subgroup among patients with stage IIIC (any TN3M0) breast carcinoma? (Annals of Surgical Oncology DOI: 10.1245/s10434-007-9558-6);Is there any prognostically different subgroup among patients with stage IIIC (anyTN3M0) breast carcinoma?

Annals of Surgical Oncology

Volumn 15, Issue 2, 2008, Pages 430-437

  Duraker, Nüvit ^a   Çaynak, Zeynep C ^a   Bati, Bakir ^a  

^a OKMEYDANI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Breast cancer; Lymph node ratio; Percentage of metastatic lymph nodes; Prognostic groups; Stage IIIC; TNM classification

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; AXILLA; BREAST TUMOR; CLASSIFICATION; LYMPH NODE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ADULT; AGED; AXILLA; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 40649098256     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-008-9826-0     Document Type: Erratum

References (30)

1. 1. FL Greene DL Page ID Fleming 2002 AJCC Cancer Staging Manual 6 Springer New York Greene FL, Page DL, Fleming ID, et al. (eds). AJCC Cancer Staging Manual. 6th ed. New York: Springer; 2002
2. 2. ID Fleming JS Cooper DE Henson 1997 AJCC Cancer Staging Manual 5 Lippincott-Raven Philadelphia Fleming ID, Cooper JS, Henson DE, et al. (eds). AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997
3. 3. N Duraker ZC Çaynak 2005 Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes Cancer 104 700 7 16003773 10.1002/cncr.21199 Duraker N, Çaynak ZC. Prognostic value of the 2002 TNM classification for breast carcinoma with regard to the number of metastatic axillary lymph nodes. Cancer 2005;104:700–7.
4. 4. MS Tallman R Gray NJ Robert 2003 Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 349 17 26 12840088 10.1056/NEJMoa030684 1:CAS:528:DC%2BD3sXltFGkurY%3D Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003;349:17–26
5. 5. AR Zander N Kröger C Schmoor 2004 High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial J Clin Oncol 22 2273 83 15111618 10.1200/JCO.2004.07.026 1:CAS:528:DC%2BD2cXpsVWltL8%3D Zander AR, Kröger N, Schmoor C, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 2004;22:2273–83
6. 6. WP Peters GL Rosner JJ Vredenburgh 2005 Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13 J Clin Oncol 23 2191 200 15767638 10.1200/JCO.2005.10.202 Peters WP, Rosner GL, Vredenburgh JJ, et al. Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 2005;23:2191–200
7. 7. RC Coombes A Howell M Emson 2005 High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomized trial Ann Oncol 16 726 34 15817602 10.1093/annonc/mdi166 1:STN:280:DC%2BD2M3gvValtg%3D%3D Coombes RC, Howell A, Emson M, et al. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomized trial. Ann Oncol 2005;16:726–34
8. 8. EO Hanrahan K Broglio D Frye 2006 Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years Cancer 106 2327 36 16639731 10.1002/cncr.21906 1:CAS:528:DC%2BD28Xls1Srurw%3D Hanrahan EO, Broglio K, Frye D, et al. Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 2006;106:2327–36.
9. 9. S Rodenhuis M Bontenbal LVAM Beex 2003 High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer N Engl J Med 349 7 16 12840087 10.1056/NEJMoa022794 1:CAS:528:DC%2BD3sXltFGkurs%3D Rodenhuis S, Bontenbal M, Beex LVAM, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 2003;349:7–16
10. 10. UA Nitz S Mohrmann J Fischer 2005 Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial Lancet 366 1935 44 16325695 10.1016/S0140-6736(05)67784-7 1:CAS:528:DC%2BD2MXht1OnurfE Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 2005;366:1935–44
11. 11. Y Nieto PJ Cagnoni EJ Shpall 1999 A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant Clin Cancer Res 5 3425 31 10589754 1:CAS:528:DyaK1MXotV2gsLg%3D Nieto Y, Cagnoni PJ, Shpall EJ, et al. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clin Cancer Res 1999;5:3425–31
12. 12. B Bolwell S Andresen B Pohlman 2001 Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer Bone Marrow Transplant 27 843 6 11477442 10.1038/sj.bmt.1703004 1:STN:280:DC%2BD38%2FgvF2ruw%3D%3D Bolwell B, Andresen S, Pohlman B, et al. Prognostic importance of the axillary lymph node ratio in autologous transplantation for high-risk stage II/III breast cancer. Bone Marrow Transplant 2001;27:843–6
13. 13. A Schneeweiss R Goerner M Hensel 2001 Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy Biol Blood Marrow Transplant 7 332 42 11464976 10.1016/S1083-8791(01)80004-5 1:CAS:528:DC%2BD3MXlslSls7k%3D Schneeweiss A, Goerner R, Hensel M, et al. Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy. Biol Blood Marrow Transplant 2001;7:332–42
14. 14. Y Nieto S Nawaz EJ Shpall SI Bearman J Murphy RB Jones 2004 Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy Clin Cancer Res 10 2609 17 15102662 10.1158/1078-0432.CCR-03-0536 1:CAS:528:DC%2BD2cXjt1Clt78%3D Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Long-term analysis and prospective validation of a prognostic model for patients with high-risk primary breast cancer receiving high-dose chemotherapy. Clin Cancer Res 2004;10:2609–17
15. 15. T Nemoto J Vana RN Bedwani HW Baker FH McGregor GP Murphy 1980 Management and survival of female breast cancer: results of a national survey by the American College of Surgeons Cancer 45 2917 24 7388735 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M 1:STN:280:Bi%2BB383ktlA%3D Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980;45:2917–24
16. 16. B Fisher M Bauer L Wickerham 1983 Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update Cancer 52 1551 7 6352003 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3 1:STN:280:BiuD3c7ot1M%3D Fisher B, Bauer M, Wickerham L, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: an NSABP update. Cancer 1983;52:1551–7
17. 17. B Kuru 2006 Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma Eur J Surg Oncol 32 1082 8 16887320 10.1016/j.ejso.2006.06.005 1:STN:280:DC%2BD28novVeqsQ%3D%3D Kuru B. Prognostic significance of total number of nodes removed, negative nodes removed, and ratio of positive nodes to removed nodes in node positive breast carcinoma. Eur J Surg Oncol 2006;32:1082–8
18. 18. BCH Wal Van der RMJM Butzelaar S Meij van der MA Boermeester 2002 Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer Eur J Surg Oncol 28 481 9 12217299 10.1053/ejso.2002.1239 Van der Wal BCH, Butzelaar RMJM, van der Meij S, Boermeester MA. Axillary lymph node ratio and total number of removed lymph nodes: predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481–9
19. 19. M Woordeckers V Vinh-Hung J Steene Van de J Lamote G Storme 2004 The lymph node ratio as prognostic factor in node-positive breast cancer Radiother Oncol 70 225 30 10.1016/j.radonc.2003.10.015 Woordeckers M, Vinh-Hung V, Van de Steene J, Lamote J, Storme G. The lymph node ratio as prognostic factor in node-positive breast cancer. Radiother Oncol 2004;70:225–30
20. 20. SA Joslyn BR Konety 2005 Effect of axillary lymphadenectomy on breast carcinoma survival Breast Cancer Res Treat 91 11 8 15868427 10.1007/s10549-004-6276-7 Joslyn SA, Konety BR. Effect of axillary lymphadenectomy on breast carcinoma survival. Breast Cancer Res Treat 2005;91:11–8.
21. 21. PT Truong E Berthelet J Lee HA Kader IA Olivotto 2005 The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes Cancer 103 2006 14 15812825 10.1002/cncr.20969 Truong PT, Berthelet E, Lee J, Kader HA, Olivotto IA. The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006–14.
22. 22. A Fortin A Dagnault L Blondeau TTT Vu M Larochelle 2006 The impact of the number of excised axillary nodes and of the percentage of involved nodes on regional nodal failure in patients treated by breast-conserving surgery with or without regional irradiation Int J Radiat Oncol Biol Phys 65 33 9 16542789 Fortin A, Dagnault A, Blondeau L, Vu TTT, Larochelle M. The impact of the number of excised axillary nodes and of the percentage of involved nodes on regional nodal failure in patients treated by breast-conserving surgery with or without regional irradiation. Int J Radiat Oncol Biol Phys 2006;65:33–9.
23. 23. I Jatoi 1999 Management of the axilla in primary breast cancer Surg Clin North Am 79 1061 73 10572551 10.1016/S0039-6109(05)70061-X 1:STN:280:DC%2BD3c%2FjvVyntA%3D%3D Jatoi I. Management of the axilla in primary breast cancer. Surg Clin North Am 1999;79:1061–73.
24. 24. WK Ruffin A Stacey-Clear J Younger HC Hoover 1995 Rationale for routine axillary dissection in carcinoma of the breast J Am Coll Surg 180 245 51 7850065 1:STN:280:ByqC2M3ptVI%3D Ruffin WK, Stacey-Clear A, Younger J, Hoover HC. Rationale for routine axillary dissection in carcinoma of the breast. J Am Coll Surg 1995;180:245–51.
25. 25. MP Moore DW Kinne 1997 Axillary lymphadenectomy: a diagnostic and therapeutic procedure J Surg Oncol 66 2 6 9290685 10.1002/(SICI)1096-9098(199709)66:1<2::AID-JSO2>3.0.CO;2-8 1:STN:280:ByiH3sngtFw%3D Moore MP, Kinne DW. Axillary lymphadenectomy: a diagnostic and therapeutic procedure. J Surg Oncol 1997;66:2–6.
26. 26. M Morrow 1999 A survival benefit from axillary dissection: was Halsted correct? Ann Surg Oncol 6 17 8 10030410 10.1007/s10434-999-0017-4 1:STN:280:DyaK1M7ltlCrsw%3D%3D Morrow M. A survival benefit from axillary dissection: was Halsted correct? Ann Surg Oncol 1999;6:17–8
27. 27. KM McMasters 2003 The eternally enigmatic axilla: further controversy about axillary lymph nodes in breast cancer Ann Surg Oncol 10 1128 30 14654464 10.1245/ASO.2003.10.917 McMasters KM. The eternally enigmatic axilla: further controversy about axillary lymph nodes in breast cancer. Ann Surg Oncol 2003;10:1128–30.
28. 28. A Luini G Gatti B Ballardini 2005 Development of axillary surgery in breast cancer Ann Oncol 16 259 62 15668280 10.1093/annonc/mdi060 1:STN:280:DC%2BD2M%2FjvFyitQ%3D%3D Luini A, Gatti G, Ballardini B, et al. Development of axillary surgery in breast cancer. Ann Oncol 2005;16:259–62.
29. 29. U Veronesi G Paganelli G Viale 2006 Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomized controlled study Lancet Oncol 7 983 90 17138219 10.1016/S1470-2045(06)70947-0 Veronesi U, Paganelli G, Viale G, et al. Sentinel-lymph-node biopsy as a staging procedure in breast cancer: update of a randomized controlled study. Lancet Oncol 2006;7:983–90.
30. 30. GH Lyman AE Giuliano MR Somerfield 2005 American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer J Clin Oncol 23 7703 20 16157938 10.1200/JCO.2005.08.001 Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703–20.